The agency has been retained by Takeda for the past two years but was nonetheless made to repitch against three undisclosed agencies to secure a contract extension for 2007 estimated to be worth around £750,000.
The new contract will continue The Remedy's work on medical meetings to support Actos (pioglitzone), Blopress (candesartan) and leuprorelin, but includes meetings for pre-launch insomnia drug ramelteon.
Projects on other drugs in Takeda's research pipeline are also being considered.
